Patients age ≥ 18 years requiring a PICC for a period of fourteen days or greater (note: maximum study period is 90 days)
Ability to comply with study requirements inclusive of the follow-up duplex ultrasound procedures and, as applicable, recording of PICC management, interventions and related treatments in the inpatient and outpatient setting in the daily subject diary
Patients cognitively and physically able to give written consent to participate in the study or patient has a legally authorized representative (LAR) who may give written consent to participate in the study
You may not be if
Previous history of (within 3 months) or current diagnosis of venous thrombosis within the venous tract of the proposed catheter
History or diagnosis of peripheral or central vein stenosis (on proposed insertion side)
History or diagnosis of veno-occlusive disease
History or diagnosis of superior vena cava syndrome
Known, pre-existing diagnosis of hypercoagulation disorder unrelated to underlying disease
Previous enrollment in this study
Currently pregnant or breast feeding
Previous axillary lymph node dissection on the same side as intended catheter insertion site unless cleared by physician and patient consent
Skin condition at or within 15 cm of the proposed catheter insertion site, including signs and symptoms of inflammation, rash, crusts, wounds with drainage, sites of intravenous infusion infiltration or extravasation, hematoma, phlebitis and or thrombophlebitis
Medical, social, and/or psychological problems precluding subject from study participation
Stage 2, 3 or 4 chronic kidney disease or serum creatinine \> 3 mg/dl or Glomerular Filtration Rate (GFR) less than 60 mL per minute per 1.73 m2 unless cleared by a nephrologist for participation
Known allergy or sensitivity to chlorhexidine
Clareo Health | Arrow Chloragard Peripherally-Inserted Central Catheters (PICC) Study
